Trial
NCT06514742
A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Depressive Disorder, Major
Intervention
Aticaprant
Why stopped
Early study termination due to insufficient efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-17